Seminars in Oncology
Volume 34, Issue 2 , Pages 135-144 , April 2007

Chemotherapy for Metastatic or Unresectable Bladder Cancer

  • Joaquim Bellmunt

      Affiliations

    • Hospital del MAR-IMAS, Autónoma University of Barcelona, Barcelona, Spain.
    • Corresponding Author InformationAddress correspondence to Joaquim Bellmunt, MD, Section Chief, Solid Tumor Oncology (GU & GI), Medical Oncology Service, Autónoma University of Barcelona, Hospital del MAR, Paseo Maritimo 25-29, Barcelona 08003, Spain.
    • ,
  • Santiago Albiol

      Affiliations

    • Clínica Quirón Barcelona, Barcelona, Spain.

References 

  1. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol. 1992;10:1066–1073
  2. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050–1055
  3. Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997;80:1966–1972
  4. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985;133:403–407
  5. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium (Efficacy and patterns of response and relapse). Cancer. 1989;64:2448–2458
  6. Harker WG, Meyers FJ, Freiha FS, et al. A Northern California Oncology Group study Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. J Clin Oncol. 1985;3:1463–1470
  7. Hillcoat BL, Raghavan D, Matthews J, et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol. 1989;7:706–709
  8. Stoter G, Splinter TA, Child JA, et al. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol. 1987;137:663–667
  9. Mead GM, Russell M, Clark P, et al. MRC Advanced Bladder Cancer Working Party A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: Results and a report on prognostic factors in a Medical Research Council study. Br J Cancer. 1998;78:1067–1075
  10. Loehrer PJ, Elson P, Dreicer R, et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: An Eastern Cooperative Oncology Group trial. J Clin Oncol. 1994;12:483–488
  11. Logothetis CJ, Finn LD, Smith T, et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial. J Clin Oncol. 1995;13:2272–2277
  12. Scher HI, Geller NL, Curley T, et al. Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. J Clin Oncol. 1993;11:400–407
  13. Seidman AD, Scher HI, Gabrilove JL, et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol. 1993;11:408–414
  14. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol. 2001;19:2638–2646
  15. Bellmunt J, Albiol S. New chemotherapy combinations for advanced bladder cancer. Curr Opin Urol. 2001;11:517–522
  16. Calabro F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol. 2002;20:158–166
  17. Calabro F, Sternberg CN. High-risk metastatic urothelial cancer: Chances for cure?. Curr Opin Urol. 2002;12:441–448
  18. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol. 1997;15:2564–2569
  19. Bellmunt J, Albanell J, Gallego OS, et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer. 1992;70:1974–1979
  20. Waxman J, Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev. 1993;19(suppl C):21–25
  21. Culine S, Rebillard X, Iborra F, et al. Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: A pilot study. Anticancer Res. 2003;23:1903–1906
  22. Font A, Esteban E, Carles J, et al. Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. J Clin Oncol. 2004;22:392s;(abstr 4544)
  23. Moore MJ, Winquist E, Vokes EE, et al. Phase II study of oxaliplatin in patients with inoperable, locally advanced or metastatic transitional cell carcinoma of the urothelial tract (TCC) who have received prior chemotherapy. Proc Am Soc Clin Oncol. 2004;22:408;(abstr 1638)
  24. Witte RS, Elson P, Khandakar J, et al. An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. Cancer. 1994;73:688–691
  25. de Wit R, Kaye SB, Roberts JT, et al. Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer. 1993;67:388–390
  26. Khorsand M, Lange J, Feun L, et al. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Invest New Drugs. 1997;15:157–163
  27. Dreicer R, Roth B, Wilding G. Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group. Cancer. 2003;97:2109–2114
  28. Misset JL. Brief communication: Use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer. Semin.Oncol. 2002;29:36–39
  29. Sternberg CN. Gemcitabine in bladder cancer. Semin Oncol. 2000;27:31–39
  30. Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol. 2003;46(suppl S):105–115
  31. von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Exp Rev Anticancer Ther. 2003;3:11–19
  32. Artz A, Stadler WM, Vogelzang NJ, et al. A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. Am J Clin Oncol. 2005;28:109–113
  33. Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15:3441–3445
  34. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15:3394–3398
  35. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18:1921–1927
  36. Moore MJ, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17:2876–2881
  37. von der Maase H, Andersen L, Crino L, et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial. Ann Oncol. 1999;10:1461–1465
  38. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–3077
  39. Burch PA, Richardson RL, Cha SS, et al. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol. 2000;164:1538–1542
  40. Dreicer R, Manola J, Roth BJ, et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group Study. J Clin Oncol. 2000;18:1058–1061
  41. Murphy BA, Johnson DR, Smith J, et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer. Proc Am Soc Clin Oncol. 1996;12:245;(abstr 617)
  42. Dimopoulos MA, Bakoyannis C, Georgoulias V, et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol. 1999;10:1385–1388
  43. Garcia del Muro X, Marcuello E, Guma J, et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer. 2002;86:326–330
  44. Sengelov L, Kamby C, Lund B, et al. Docetaxel and cisplatin in metastatic urothelial cancer: A phase II study. J Clin Oncol. 1998;16:3392–3397
  45. Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:220–228
  46. Redman BG, Smith DC, Flaherty L, et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol. 1998;16:1844–1848
  47. Small EJ, Lew D, Redman BG, et al. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol. 2000;18:2537–2544
  48. Vaughn DJ, Malkowicz SB, Zoltick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen. J Clin Oncol. 1998;16:255–260
  49. Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004;100:1639–1645
  50. Petrioli R, Frediani B, Manganelli A, et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients (A randomized phase II study). Cancer. 1996;77:344–351
  51. Carteni G, Dogliotti L, Crucitta E, et al. Phase II randomized trial of gemcitabine plus cisplatin (GP) and gemcitabine plus carboplatin (GC) in patients (pts) with advanced or metastatic transitional cell carcinoma of the urothelium (TCCU). J Clin Oncol. 2003;22:384s;(abstr 1543)
  52. Bellmunt J, de Wit R, Albanell J, et al. A feasibility study of carboplatin with fixed dose of gemcitabine in “unfit” patients with advanced bladder cancer. Eur J Cancer. 2001;37:2212–2215
  53. Bajorin DF, McCaffrey JA, Dodd PM, et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules. Cancer. 2000;88:1671–1678
  54. Dodd PM, McCaffrey JA, Hilton S, et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol. 2000;18:840–846
  55. Maluf FC, Bajorin DF. Chemotherapy agents in transitional cell carcinoma: the old and the new. Semin Urol Oncol. 2001;19:2–8
  56. Novick S, Higgins G, Hilton S, et al. Phase I/II sequential doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with transitional cell carcinoma and impaired renal function. Proc Am Soc Clin Oncol. 2000;19:361;(abstr 1423)
  57. Bellmunt J, Guillem V, Paz-Ares L, et al. Spanish Oncology Genitourinary Group Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol. 2000;18:3247–3255
  58. Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001;19:2527–2533
  59. Hainsworth JD, Meluch AA, Litchy S, et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 2005;103:2298–2303
  60. Edelman MJ, Meyers FJ, Miller TR, et al. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: A well-tolerated regimen with activity independent of p53 mutation. Urology. 2000;55:521–525
  61. Tu SM, Hossan E, Amato R, et al. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol. 1995;154:1719–1722
  62. Pectasides D, Visvikis A, Aspropotamitis A, et al. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer (Phase II trial). Eur J Cancer. 2000;36:74–79
  63. Law LY, Lara PN, Meyers FJ, et al. Platinum free combination chemotherapy in locally advanced and metastatic transitional cell carcinoma: Phase I/II trial of gemcitabine, paclitaxel, methotrexate. J Clin Oncol. 2001;20:192a;(abstr 767)
  64. Dodd PM, McCaffrey JA, Herr H, et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol. 1999;17:2546–2552
  65. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173–3181
  66. Stadler WM, Hayden A, von der Maase H, et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol. 2002;7:153–157
  67. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–4608
  68. Bellmunt J, Albanell J, Paz-Ares L, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer. 2002;95:751–757
  69. Siefker-Radtke AO, Millikan RE, Tu SM, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol. 2002;20:1361–1367
  70. Linardou H, Aravantinos G, Efstathiou E, et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology. 2004;64:479–484
  71. Turkolmez K, Beduk Y, Baltaci S, et al. Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy. Eur Urol. 2003;44:682–686
  72. Vaughn D, Dreicer R, Manola J, et al. E2896 paclitaxel/carboplatin in advanced urothelial carcinoma and renal insufficiency: A phase II trial of the Eastern Cooperative Group. Proc Am Soc Clin Oncol. 2000;19:343;(abstr 1351)
  73. Ardavanis A, Tryfonopoulos D, Alexopoulos A, et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: A phase II study. Br J Cancer. 2005;92:645–650
  74. Fechner G, Siener R, Reimann M, et al. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract. 2006;60:27–31
  75. Gitlitz BJ, Baker C, Chapman Y, et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer. 2003;98:1863–1869
  76. Guardino AE, Srinivas S. Gemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies. Proc Am Soc Clin Oncol. 2002;21:150b;(abstr 321)
  77. Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2001;19:3018–3024
  78. Parameswaran R, Fisch MJ, Ansari RH, et al. A Hoosier Oncology Group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder. Proc Am Soc Clin Oncol. 2001;20:(abstr 798)
  79. Sternberg CN, Calabro F, Pizzocaro G, et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001;92:2993–2998
  80. Kaufman DS, Carducci MA, Kuzel TM, et al. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004;22:393–397
  81. Bellmunt J, Cos J, Cleries R, et al. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest. 2002;20:673–685
  82. Di Lorenzo G, Autorino R, Giordano A, et al. FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. Jpn J Clin Oncol. 2004;34:747–750
  83. Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol. 1997;15:589–593
  84. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15:1853–1857
  85. de Wit R, Kruit WH, Stoter G, et al. Docetaxel (Taxotere): An active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer. 1998;78:1342–1345
  86. Paz-Ares L, Tabernero J, Moyano A, et al. A phase II of the multi-targeted antifolate, MTA (LY231514), in patients with advanced transitional cell carcinoma of the bladder. Proc Am Soc Clin Oncol. 1998;14:339;(abstr 1307)
  87. Sweeney C, Roth BJ, Kaufman DS, et al. Phase II study of pemetrexed (pem) for second-line treatment of transitional cell cancer (tcc) of the bladder. Proc Am Soc Clin Oncol. 2003;22:411;(abstr 1653)
  88. Bui C, Theodore S, Culine E, et al. Preliminary results of a phase II study testing intravenous (iv) vinflunine (VFL) as second line therapy in patients with advanced transitional cell cancer (TCC) of the bladder. Proc Am Soc Clin Oncol. 2003;22:391;(abstr 1571)
  89. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer (Therapy of bladder cancer by blockade of the epidermal growth factor receptor family). Crit Rev Oncol Hematol. 2003;46(suppl):S85–S104
  90. Geller NL, Sternberg CN, Penenberg D, et al. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer. 1991;67:1525–1531
  91. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8:2286–2291
  92. Petrylak DP, Scher HI, Reuter V, et al. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol. 1994;5:835–840
  93. Pendyala L, Velagapudi S, Toth K, et al. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res. 1997;3:793–798
  94. Siu LL, Banerjee D, Khurana RJ, et al. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res. 1998;4:559–565
  95. Cordon-Cardo C, Zhang ZF, Dalbagni G, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 1997;57:1217–1221
  96. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331:1259–1264
  97. Zhang ZT, Pak J, Huang HY, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene. 2001;20:1973–1980
  98. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol. 1995;13:1384–1390
  99. Chow NH, Chan SH, Tzai TS, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res. 2001;7:1957–1962
  100. Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours. Lancet. 1985;1:366–368
  101. Inoue K, Kamada M, Slaton JW, et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res. 2002;8:1863–1870
  102. Izawa JI, Sweeney P, Perrotte P, et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res. 2002;8:1258–1270
  103. Slaton JW, Inoue K, Perrotte P, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol. 2001;158:735–743
  104. Slaton JW, Millikan R, Inoue K, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004;171:570–574
  105. Al-Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer. 2003;97:2064–2075
  106. Raghavan D. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer. 2003;97:2083–2089
  107. Salonga DS, Danenberg KD, Grem J, et al. Relative gene expression in normal and tumor tissue by quantitative RT-PCR. Methods Mol Biol. 2002;191:83–98
  108. Rosell R, Taron M, Ariza A, et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol. 2004;31:20–27
  109. Selvakumaran M, Pisarcik DA, Bao R, et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003;63:1311–1316
  110. Dabholkar M, Bostick-Bruton F, Weber C, et al. Expression of excision repair genes in non-malignant bone marrow from cancer patients. Mutat Res. 1993;293:151–160
  111. Britten RA, Liu D, Tessier A, et al. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer. 2000;89:453–457
  112. Dabholkar M, Vionnet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest. 1994;94:703–708
  113. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998;16:309–316
  114. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001;19:4298–4304
  115. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003;63:6221–6228
  116. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 2004;13:2443–2449
  117. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2004;10:1318–1325
  118. Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene. 2003;22:3548–3553
  119. Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 2004;64:3761–3766
  120. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol. 2005;288:C494–C506
  121. Kim HA, Kim KH, Lee RA. Expression of caveolin-1 is correlated with Akt-1 in colorectal cancer tissues. Exp Mol Pathol. 2006;80:165–170
  122. Yang CP, Galbiati F, Volonte D, et al. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett. 1998;439:368–372
  123. Sunaga N, Miyajima K, Suzuki M, et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res. 2004;64:4277–4285
  124. Bajorin DF, Bellmunt J, Bochner BH, et al. Changing paradigms in advanced bladder cancer. In: ASCO Bladder Educational Book. 2005;p. 330–350
  125. Sanchez-Carbayo M, Socci ND, Charytonowicz E, et al. Molecular profiling of bladder cancer using cDNA microarrays: Defining histogenesis and biological phenotypes. Cancer Res. 2002;62:6973–6980
  126. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet. 2003;33:90–96
  127. Primdahl H, Wikman FP, von der Maase H, et al. Allelic imbalances in human bladder cancer: Genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst. 2002;94:216–223
  128. Thykjaer T, Workman C, Kruhoffer M, et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res. 2001;61:2492–2499
  129. Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer. 2003;89:2172–2177
  130. Duggan BJ, McKnight JJ, Williamson KE, et al. The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. Clin Cancer Res. 2003;9:1240–1247
  131. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24:778–789

PII: S0093-7754(06)00485-4

doi: 10.1053/j.seminoncol.2006.12.008

Seminars in Oncology
Volume 34, Issue 2 , Pages 135-144 , April 2007

Article Tools

* Image Usage & Resolution